ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance Corporation announced today that it has concluded an agreement with Provecs Medical GmbH, a company based in Hamburg, Germany, for production of investigational quantities of Immunalon®, a novel therapeutic agent based upon an adenovirus vector that stimulates an immunological response against tumor cells.
